Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) and Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.
Valuation & Earnings
This table compares Nautilus Biotechnology and Maravai LifeSciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nautilus Biotechnology | N/A | N/A | -$59.00 million | ($0.45) | -2.04 |
| Maravai LifeSciences | $185.74 million | 10.30 | -$130.77 million | ($0.52) | -14.17 |
Profitability
This table compares Nautilus Biotechnology and Maravai LifeSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nautilus Biotechnology | N/A | -37.58% | -30.83% |
| Maravai LifeSciences | -37.07% | -15.70% | -8.17% |
Risk and Volatility
Nautilus Biotechnology has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Nautilus Biotechnology and Maravai LifeSciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nautilus Biotechnology | 1 | 0 | 1 | 0 | 2.00 |
| Maravai LifeSciences | 2 | 0 | 2 | 0 | 2.00 |
Nautilus Biotechnology currently has a consensus target price of $4.00, indicating a potential upside of 335.02%. Maravai LifeSciences has a consensus target price of $6.25, indicating a potential downside of 15.20%. Given Nautilus Biotechnology’s higher possible upside, equities analysts plainly believe Nautilus Biotechnology is more favorable than Maravai LifeSciences.
Institutional & Insider Ownership
50.7% of Nautilus Biotechnology shares are held by institutional investors. Comparatively, 50.2% of Maravai LifeSciences shares are held by institutional investors. 41.1% of Nautilus Biotechnology shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Nautilus Biotechnology beats Maravai LifeSciences on 8 of the 12 factors compared between the two stocks.
About Nautilus Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
